RxDoctor Payments Data

Jessica Gillespie, MD

Internal Medicine · Olathe, KSNPI 1902070261

Payments from drug & device makers

$609in general payments, 2019–2025

Across 37 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$145
  • Novo Nordisk$125
  • AbbVie$72
  • Amgen$54
  • AstraZeneca$43
  • Supernus Pharmaceuticals, Inc.$42
  • plus $129 from 6 others

What the payments were for

  • Food & beverage$609100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$609 in reported general payments places this provider in the 70th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$90,572
Medicare patients
247
Services billed
1,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$111,851
EliquisApixaban84$95,422
MounjaroTirzepatide47$73,343
JardianceEmpagliflozin48$51,616
FarxigaDapagliflozin Propanediol45$40,442
Tresiba Flextouch U-200Insulin Degludec31$32,916
TrulicityDulaglutide14$22,635
JanuviaSitagliptin Phosphate12$19,231
MyrbetriqMirabegron21$16,655
VraylarCariprazine Hcl11$15,655
Breo ElliptaFluticasone/Vilanterol16$12,284
LinzessLinaclotide18$11,668
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,011
Combivent RespimatIpratropium/Albuterol Sulfate16$7,513
Rosuvastatin Calcium208$4,786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$125$111,85190 claims
Lilly USA, LLCMounjaro, Trulicity$145$95,97861 claims
PfizerEliquis$15$95,42284 claims
AstraZenecaFarxiga$43$40,44245 claims
AbbVieVraylar, Linzess, Synthroid$72$30,45177 claims
GSKBreo Ellipta, Trelegy Ellipta$26$21,29530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Olathe

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →